Spine Wave has begun a clinical study to determine the feasibility of implanting its NuCore injectable nucleus device using a proprietary percutaneous technique to treat degenerative disc disease.
NuCore material consists of rDNA-based protein polymer and a transient radiopacifier, which allows the material to be visualised intra-operatively during percutaneous injection.
Go deeper with GlobalData
The NuCore material will relieve pain, maintain disc height and restore biomechanical function in degenerative disc disease patients.
Dr Ulrich Berlemann of the Spine Center in Thun, Switzerland, said the initial results from an ongoing study involving the device have shown considerable reductions in pain scores within the three month post-operative evaluation.
Spine Wave chairman and CEO Mark LoGuidice said that the study will be an add-on to the previous clinical work, which demonstrated the device’s safety and that it could maintain disc height.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
